The Institute of Medicine has made patient-centered care a cornerstone in a strategy to improve healthcare in the U.S. This week offers proof that cardiovascular thought leaders are listening, plus one word of warning.

Patients with diabetes and multivessel coronary artery disease (CAD) experience no long-term differences in quality of life whether they undergo PCI or CABG, a FREEDOM trial substudy found. The results were published in the Oct. 16 issue of the JAMA.

Stroke is the second leading cause of death in Los Angeles County and the fourth in the U.S. In order to cut those numbers, it's imperative that new treatments be developed and refined for stroke prevention, acute therapy and recovery after stroke.

BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, announced a significant milestone today in the development of a new therapy era for patients suffering from coronary artery disease. As part of the clinical study BIOSOLVE-II, Prof. Dr. Michael Haude from the Lukaskrankenhaus, Neuss, Germany, successfully implanted the BIOTRONIK DREAMS (DRug Eluting Absorbable Metal Scaffold) in the first patient.

Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF.PK), is pleased to announce that the United States Food and Drug Administration (FDA) has approved the AGGRASTAT (tirofiban HCl) high-dose bolus (HDB) regimen, as requested under Medicure's supplemental New Drug Application (sNDA). The AGGRASTAT HDB regimen (25 mcg/kg over 3 minutes, followed by 0.15 mcg/kg/min) now becomes the recommended dosing for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome (NSTE-ACS).

AccessClosure, Inc., the market leader in extravascular closure devices, announced today an exclusive agreement with Ostial Corporation to distribute the Flash Ostial System Dual Balloon Angioplasty Catheter in the United States. The Flash Ostial System is designed to help overcome the challenges of aorto-ostial stenting and compliments the Mynx® Product Family of Vascular Closure Devices to expand AccessClosure’s portfolio.

BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced the launch of the new Idova 7 series today. Idova 7 ICDs (implantable cardioverter-defibrillators) and CRT-Ds (cardiac resynchronization therapy defibrillators) offer ultrahigh-energy therapy without compromising on short charge times (10 sec), smaller size (34 cc), and outstanding longevity of more than eleven years. Designed to stop life-threatening arrhythmias with the very first shock, Idova 7 gives patients valuable peace of mind.

The Cardiovascular Care Group (TCVCG), announced today it has united with The Vein Institute of New Jersey to offer patients access to an expanded team of highly skilled clinicians with outstanding results and additional locations throughout Central and Northern New  Jersey. Reinforcing its commitment to producing great outcomes for the millions of Americans who have varicose and spider veins, the merger increases the number of board–certified physicians available to patients further enabling The Vein Institute at TCVCG to meet the growing demand for its services.